Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bexotegrast - Pliant Therapeutics

Next Previous
Search
Drug Profile

Bexotegrast - Pliant Therapeutics

Alternative Names: PLN-74809

Latest Information Update: 13 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pliant Therapeutics
  • Class Anti-inflammatories; Antifibrotics; Butyric acids; Naphthyridines; Quinazolines; Small molecules
  • Mechanism of Action Integrin alphavbeta1 inhibitors; Integrin alphavbeta8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis; Primary sclerosing cholangitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Idiopathic pulmonary fibrosis
  • Phase II Primary sclerosing cholangitis
  • No development reported Primary biliary cirrhosis
  • Discontinued SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 07 Feb 2025 Pliant Therapeutics suspends a phase II/III BEACON-IPF trial in Idiopathic pulmonary fibrosis in the USA, Argentina, Australia, Belgium, Canada, Chile, Czechia, Denmark, France, Israel, South Korea, Netherlands, New Zealand, Spain, Taiwan, United Kingdom, Brazil, China, Germany, Greece, India, Italy, Japan, Poland, Portugal (PO), following a prespecified data review and recommendations by the trial’s independent Data Safety Monitoring Board (DSMB) (NCT06097260)
  • 28 Sep 2024 No recent reports of development identified for preclinical development in Primary-biliary-cirrhosis in USA (PO, Tablet)
  • 07 Sep 2024 Efficacy, adverse event and pharmacodynamics data from the phase IIa INTEGRIS-IPF trial in Idiopathic pulmonary fibrosis presented at the 34th Annual Congress of the European Respiratory Society (ERS-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top